CSBio CSBio

X
[{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Positive Results from Phase II BHT-II-002 Trial of Blautix in Irritable Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"4D Pharma"},{"orgOrder":0,"company":"GSK","sponsor":"Immutep","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces that the Phase II Ulcerative Colitis Study of GSK2831781 Has Been Discontinued","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"GSK"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D pharma to Present Additional Data from Phase II Study of Blautix for Irritable Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"4D Pharma"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix\u00ae for IBS-C and IBS-D at Gastro 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"4D Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Results demonstrate changes in gut microbiome structure following administration of Blautix (Blautia Hydrogenotrophica) in both IBS-C and IBS-D patients.

            Lead Product(s): Blautia Hydrogenotrophica

            Therapeutic Area: Gastroenterology Product Name: Blautix

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In Phase II trial, where Blautix demonstrated signals of clinical activity in both IBS-C and IBS-D, and a highly favorable safety and tolerability profile.

            Lead Product(s): Blautia Hydrogenotrophica

            Therapeutic Area: Gastroenterology Product Name: Blautix

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 17, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            GSK

            Contact Supplier
            • Development Update

            Details:

            GSK, has stopped its Phase II trial of anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative colitis. The trial was stopped based on the assessment of clinical data of planned interim analysis.

            Lead Product(s): IMP731

            Therapeutic Area: Gastroenterology Product Name: GSK2831781

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Immutep

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The phase II trial showed that Blautix treatment resulted in: A statistically significant increase in overall response in pre-planned analysis of the combined IBS-C/D group compared to placebo; A positive, increase in overall response in both IBS-C and IBS-D cohorts.

            Lead Product(s): Blautia Hydrogenotrophica

            Therapeutic Area: Gastroenterology Product Name: Blautix

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY